September 17, 2024 in Publications ESMO 2024 Poster: A phase 1 study of the Myeloid-derived suppressor cells modulator HF1K16 in refractory and metastatic cancer patients: preliminary efficacy and safety. PJWCreative 0 Like Post Comments Off on ESMO 2024 Poster: A phase 1 study of the Myeloid-derived suppressor cells modulator HF1K16 in refractory and metastatic cancer patients: preliminary efficacy and safety. Click here Read More
English 
简体中文